Corey S. Goodman, Ph.D., is a scientist, educator, and biotech entrepreneur and investor. Corey is Managing Partner and co-founder of venBio, a strategic capital biotech investment firm based on a new model of strategic collaboration with pharmaceutical and biotechnology companies including Amgen, Baxter, and PPD. He is Chair of the Board of four biotechnology companies, and Board member of two others.

Born in Chicago, Corey attended Stanford University as a Searle Scholar and earned his B.S. in Biology with distinction and honors. He was an NSF Fellow at the University of California Berkeley and earned his Ph.D. in Neurobiology. He was then a Helen Hay Whitney Postdoctoral Fellow at U.C. San Diego. Corey spent 25 years as a biology professor at Stanford and U.C. Berkeley, where he was Evan Rauch Chair of Neurobiology, co-founder of the Wills Neuroscience Institute, Head of the Division of Neurobiology, and an Investigator of the Howard Hughes Medical Institute. He is currently on the faculty of U.C. San Francisco. During his academic career, Corey published over 200 scientific papers.

He is an elected member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. Corey is the recipient of numerous honors including the Alan T. Waterman Award from the National Science Board, Canada Gairdner Biomedical Award, March-of-Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, and Trinity College Dublin Dawson Prize in Genetics.

Corey moved into biotech to apply biomedical discoveries to human health. He co-founded four biotech companies -- Exelixis, Renovis, Second Genome, and Ossianix -- and led Renovis as President and CEO from a private to public company until its acquisition by Evotec.

He was recruited as President and founder of Pfizer's Biotherapeutics and Bioinnovation Center and a member of Pfizer's executive leadership team, based on a new entrepreneurial R&D model of small units at major academic and biotech hubs fostering innovative drug discovery and game-changing technology. He left Pfizer in 2009 to return to the Bay Area biotechnology community.

Amongst his many other public policy roles, Corey is on the Board of the Pacific Institute, the Bay Area Science and Innovation Consortium, and is former Chair of the National Academy of Sciences' Board on Life Sciences and former President of the McKnight Endowment Fund for Neuroscience. He is an advisor to numerous biomedical foundations, and a member of the editorial board of Science Translational Medicine and Neuron.